This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

M&A - Novartis - Regulus Therapeutics

Novartis has agreed to acquire Regulus Therapeutics, a biopharmaceutical company that develops medicines targeting microRNAs, for $7 per share in cash, with the potential for an additional $7 per share in cash through a contingent value right. The deal has an upfront value of $0.8 billion and a potential total equity value of $1.7 billion. The companies expect to complete the transaction in the second half of 2025.


To add details to this portfolio regarding legal or economic representatives, please contact editors@mlex.com.

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login